Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07253961
Starting soon Not applicable

Cold-Induced Vagal Stimulation for Attenuating Venipuncture Pain in Obese Individuals

NCT07253961 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-12-01
Last updated
2025-11-28

Condition(s) studied

Venipuncture PainVagal Nerve StimulationCold Stimulation

Investigational drug(s) / intervention(s)

Cold Application to Lateral Neck Region

Cold Application to Lateral Neck Region: Application of a marble stone cooled to 0-4°C on the lateral neck (over the sternocleidomastoid muscle) for 5 seconds prior to venous cannulation to stimulate the vagus nerve.

Study summary

This prospective, randomized controlled clinical trial aims to evaluate the effect of lateral neck cold application for vagal nerve stimulation on pain perception during peripheral venous cannulation in obese patients. Venous cannulation is a routine but painful procedure, especially in individuals with a body mass index (BMI) greater than 30, who often have heightened pain sensitivity due to chronic inflammation.

Participants will be randomly assigned to one of two groups:

Group 1 (Cold Application Group): A cold marble stone (0-4°C) will be applied to the lateral neck region (over the sternocleidomastoid muscle) for 5 seconds immediately before venous cannulation.

Group 2 (Control Group): Standard venous cannulation will be performed without any prior intervention.

Pain intensity will be assessed using the Visual Analog Scale (VAS) immediately after cannulation. Hemodynamic parameters (heart rate, blood pressure, oxygen saturation, respiratory rate) will be recorded before and after the procedure.

The primary outcome is the difference in VAS scores between the two groups. Secondary outcomes include changes in hemodynamic parameters. The study will enroll 150 participants over approximately two months following ethics approval.

Eligibility

Sex
ALL
Min age
18 Years
Max age
72 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18-72 years * physical status I-III * Scheduled for elective surgery * Body Mass Index (BMI) \> 30 kg/m² * Provided written informed consent Exclusion Criteria: * Emergency surgical cases * Oncologic surgery * Pregnant patients * History of hand dorsum surgery or scarring * Psoriasis or other local skin lesions/infections at cannulation site * Peripheral vascular disease * Chronic analgesic, opioid, steroid, or gabapentinoid use * Substance abuse history * Peripheral neuropathy * Previous or ongoing oncologic treatment * Severe mental retardation or communication impairment preventing cooperation

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Istinye Üniversity Istanbul Merkez Mahallesi

More Istinye University trials in Turkey

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07253961 on ClinicalTrials.gov ↗ ← All trials in Turkey